XML 104 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity - Stock Options (Details)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
May 08, 2020
shares
Allergan plc        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock options issued to Allergan's equity award holders (in shares) | shares [1]       11,200
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Contractual term 10 years      
Incremental vesting 0.33      
Vesting period 3 years      
Exercise price for awards granted as percentage of market value on the date of grant 100.00%      
Weighted-average grant-date fair value of the stock options granted (in dollars per share) | $ / shares $ 16.28 $ 12.14 $ 12.54  
Options        
Outstanding at the beginning of the period (in shares) | shares 15,691      
Granted (in shares) | shares 1,147      
Exercised (in shares) | shares (4,278)      
Lapsed and forfeited (in shares) | shares (186)      
Outstanding at the end of the period (in shares) | shares 12,374 15,691    
Exercisable at the end of the period (in shares) | shares 9,424      
Weighted- average exercise price        
Outstanding at the beginning of the period (in dollars per share) | $ / shares $ 73.90      
Granted (in dollars per share) | $ / shares 105.94      
Exercised (in dollars per share) | $ / shares 57.77      
Lapsed and forfeited (in dollars per share) | $ / shares 105.28      
Outstanding at the end of the period (in dollars per share) | $ / shares 81.98 $ 73.90    
Exercisable at the end of the period (in dollars per share) | $ / shares $ 78.03      
Weighted-average remaining life (in years)        
Outstanding 4 years 8 months 12 days 4 years 8 months 12 days    
Exercisable 3 years 7 months 6 days      
Aggregate intrinsic value        
Outstanding | $ $ 661 $ 559    
Exercisable | $ 541      
Aggregate intrinsic value of options exercised | $ 239 $ 186 $ 22  
Total fair value of options vested | $ 21      
Unrecognized compensation cost | $ $ 10      
Period for recognition of unrecognized compensation cost 2 years      
[1] Represents the pre-acquisition service portion of the fair value of 11 million AbbVie stock options and 8 million RSUs issued to Allergan equity award holders.